Results 61 to 70 of about 2,458 (200)
Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome
Frontiers in PharmacologyGraphical AbstractIC50 = 11 nM (PI3Kδ); 244 nM (PI3Kα); 424 nM (PI3Kβ), 2,230 nM (PI3Kγ).
Surya K. De, Surya K. De
doaj +1 more source
Prognosis and new therapeutic approaches in chronic lymphocytic leukemia treatment [PDF]
Medicinski Podmladak, 2019 Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world, comprising about 30% of all leukemias in Europe and United States. Also, it represents one of the most active hematological disease regarding clinical trials. Nearly 80%
Otašević Vladimir +2 more
doaj
Advanced Science, Volume 13, Issue 12, 27 February 2026.Plasticity changes of molecular networks form a cellular learning process. Signaling network plasticity promotes cancer, metastasis, and drug resistance development. 55 plasticity‐related cancer drug targets are listed (20 having already approved drugs, 9 investigational drugs, and 26 being drug target candidates).
Márk Kerestély +5 more
wiley +1 more source
A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204) [PDF]
, 2023 Parsaclisib, a potent and highly selective PI3K5 inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell lymphomas.
Avigdor, Abraham +15 more
core +2 more sources
ChemistryOpen, Volume 15, Issue 2, February 2026.Rationally designed naphthyl pyrazino‐pyrido‐pyrimidinones 3 and 4 inhibited 85%–94% of cancer cell growth. Compound 4 exhibited IC50 = 7.8–12.8 µM with tumor selectivity. Both induced G1 arrest and modulated ULK1, STAT3, alpha‐serine/protein kinase B (AKT), and autophagy via phosphoinositide 3‐kinase/mammalian target of rapamycin (PI3K/mTOR ...
Marcelo F. Marchiori +6 more
wiley +1 more source
The expression and signalling patterns of CD180 toll like receptor in Chronic Lymphocytic Leukaemia (CLL) [PDF]
, 2019 Chronic lymphocytic leukaemia (CLL) is characterised by a progressive accumulation of mature CD5+CD20+CD23+ lymphocytes. Despite the remarkable progress in our understanding of the immunobiology of CLL, the aetiology of the disease remains unknown.
Sayed, U., Sayed, U.
core
Targeted therapy in chronic lymphocytic leukemia [PDF]
, 2020 Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of mature B lymphocytes in blood, bone marrow and lymphoid tissues. Historically, patients with TP53 aberration and with refractoriness to chemoimmunotherapy had a dismal prognosis.
Winqvist, Maria
core +1 more source
Targeting the tumor microenvironment in chronic lymphocytic leukemia [PDF]
, 2021 he tumor microenvironment (TME) plays an essential role in the development, growth, and survival of the malignant B-cell clone in chronic lymphocytic leukemia (CLL).
Janum, Sine +4 more
core +2 more sources
A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens
Cancer, Volume 131, Issue 21, 1 November 2025.ABSTRACT Advances in the prognostication, monitoring, and treatment of both the acute and chronic leukemias have led to drastically improved outcomes over the past 2 decades. With the advent of targeted therapies, including antibodies such as blinatumomab and inotuzumab and small molecule inhibitors, such as the BCR::ABL1 tyrosine kinase inhibitors ...
Hagop M. Kantarjian +13 more
wiley +1 more source
Frontiers in Oncology, 2022 During the last two decades, kinase inhibitors have become the major drug class for targeted cancer therapy. Although the number of approved kinase inhibitors increases rapidly, comprehensive in vitro profiling and comparison of inhibitor activities is ...
Jeffrey J. Kooijman +13 more
doaj +1 more source